Price movement over the last 24 hours
ACADIA Pharmaceuticals Inc. vs Emerson Electric Co. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Emerson Electric Co. trades at $135.57 (market cap $77.24B). The key difference: Emerson Electric Co. is far larger — about 17.2× ACADIA Pharmaceuticals Inc.'s market cap, and Emerson Electric Co. pays a 1.61% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | EMR | |
|---|---|---|
Market Cap | $4.49B | $77.24B |
Sector | Health | Industrials |
52-Week High | $28.06 | $161.69 |
52-Week Low | $20.06 | $123.30 |
Enterprise Value | $3.69B | $89.51B |
Dividend Yield | — | 1.61% |
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Emerson Electric (EMR) trades at $137.91, down 0.82% on the day, with a neutral technical signal and mixed earnings history. The company maintains solid profitability with a 52.67% gross margin and 13.35% net margin, though ROE is modest at 3.05%. Recent news highlights collaboration with Aramco on corrosion R&D and positive momentum in its Intelligent Devices segment, while cash flow trends show volatility with a net outflow of $2.04B in 2025.
The outlook is cautiously optimistic, supported by a majority analyst buy rating and a $157.60 consensus price target implying 14% upside. Key risks include fluctuating cash flows, elevated debt levels, and competitive pressures in the industrial automation sector. Earnings growth and segment execution remain critical for sustained stock appreciation.
Trailing returns across standard periods
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →Emerson Electric is a multi-industrial conglomerate that operates under two business platforms: automation solutions and commercial and residential solutions. The latter is further subdivided into two operating segments: climate technologies, which sells HVAC and refrigeration products and services as well as tools and home products, which sells tools and compressors, among other products and services. Commercial and residential solutions boasts several household brands, including Copeland and RIDGID. Automation solutions is most known for its process manufacturing solutions, which consists of measurement instrumentation, as well as valves and actuators, among other products and services. Roughly half of the firm's geographic sales take place in the United States.
Read more on EMR →